NewAmsterdam Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Recommending Marketing Authorization For Ubeslo, Evlarco To Treat Primary Hypercholesterolemia
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of
A group of medicine experts said two new drugs by NewAmsterdam are safe and work well enough to sell in Europe. This is a big step forward because it means the company's hard work is paying off and people who need these medicines might get them soon.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.